New hope for AML: Three-Drug combo aims to boost remission
NCT ID NCT07486479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new combination of drugs (venetoclax, azacitidine, and a liposomal form of mitoxantrone) against the standard therapy for adults newly diagnosed with acute myeloid leukemia (AML). The study will enroll 204 people aged 18-65 to see if the new combo leads to more complete remissions. The goal is to find a more effective initial treatment for this aggressive blood cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax, azacitidine, and mitoxantrone hydrochloride liposome
What this could lead to
If successful, this could offer a more effective first-line treatment option for people with newly diagnosed AML, potentially leading to higher remission rates.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The new combination may not be more effective than the standard treatment and could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
Contact
Contact
-
Changzhou First People's Hospital
Changzhou, Jiangsu, 213003, China
Contact
-
Huai'an Second People's Hospital
Huai'an, Jiangsu, 223002, China
Contact
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Contact
Contact
-
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, 210029, China
Contact
-
Jingjiang People's Hospital
Jingjiang, Jiangsu, 214500, China
Contact
-
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, 225001, China
-
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Contact
-
Shandong First Medical University Affiliated Tumor Hospital
Jinan, Shandong, China
Contact
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
Contact
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, 41003, China
Contact
-
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, 315010, China
Contact
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
Contact
Contact
-
The First People's Hospital Of Lianyungang
Lianyungang, Jiangsu, 222002, China
Contact
-
The Second People's Hospital of Lianyungang
Lianyungang, Jiangsu, 222006, China
Contact
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Contact
-
Wuxi People's Hospital
Wuxi, Jiangsu, 214023, China
Contact
-
YanCheng NO.1 People's Hospital
Yancheng, Jiangsu, 224006, China
Contact
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Contact